Holen Sie sich die Stockscreener-App
47.85
2.79%
1.30
Handel nachbörslich:
47.74
-0.11
-0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks - The Motley Fool
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr
Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily
Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN
Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com
Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Dividend Stocks for August 2025 - Morningstar
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha
BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance
BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com
Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews
Bristol-Myers Squibb (BMY) Is Down 8.7% After Lowering Guidance Amid Strategic Shift and Generic Pressure - simplywall.st
Bristol-Myers Squibb: Buy The Weakness (NYSE:BMY) - Seeking Alpha
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 To Go Ex-Dividend On August 5th, 2025 With 0.5 USD Dividend Per Share - 富途牛牛
What makes Bristol Myers Squibb Company Equity Right stock price move sharplyExceptional earning trajectories - Jammu Links News
Bristol-Myers Squibb: Declines Have Gone Too Far (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu - Insider Monkey
Bristol-Myers Squibb Reports Strong Q2 2025 Results - The Globe and Mail
Bristol-Myers Squibb: No Respect For Blowout EarningsBuy The Richer Dividend Yields - Seeking Alpha
Bristol Myers Squibb presents new PROTACs for autoimmune and inflammatory disorders - BioWorld MedTech
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges - TipRanks
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz - pehub.com
11 Best Medical Stocks to Buy According to Analysts - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: Robust Growth and Strategic ... By GuruFocus - Investing.com Canada
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: - GuruFocus
What are the technical indicators suggesting about Bristol Myers Squibb Company Equity RightAI Powered Review For 2025 - jammulinksnews.com
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 - Insider Monkey
Bristol-Myers Squibb Earnings: A Strong Second Quarter, but Upcoming Data Readouts in Focus - Morningstar
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol Myers tops revenue expectations on strength of older drugs, shares fall By Reuters - Investing.com
Earnings call transcript: Bristol-Myers Squibb Q2 2025 sees earnings beat but stock dips - Investing.com Canada
Bristol Myers tops revenue expectations on strength of older drugs, shares fall - MarketScreener
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
Bristol Myers posts better-than-expected second quarter results on strength of top sellers - Bilyonaryo Business News
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic - Yahoo Finance
Bristol Myers raises guidance as Q2 results beat forecasts - The Pharma Letter
Bristol Myers Squibb Q2 2025 Earnings Call Transcript - MarketBeat
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion - Yahoo Finance
Is Wall Street Bullish or Bearish on Bristol-Myers Stock? - Yahoo Finance
Bristol-Myers Squibb stock hits 52-week low at 43.89 USD - Investing.com Nigeria
Bristol-Myers Squibb Co reports results for the quarter ended June 30Earnings Summary - TradingView
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):